

NCCN Melanoma Guidelines V.2.2012 – Follow-up Teleconference – 09/02/11

Guideline Page and Request	Panel Discussion	References	Vote		
			YES	NO	ABSTAIN
<p>ME-E</p> <p>Internal request: Based on the recent FDA approval, review the data for vemurafenib for inclusion in the Melanoma Guidelines as a systemic therapy option for the treatment of advanced or metastatic melanoma.</p> <p>External request: Submission from Genentech, Inc. to consider the available data on the use of vemurafenib for the treatment of patients with unresectable or metastatic melanoma.</p>	<p>Based on the recent FDA approval and supporting data in the noted reference, the panel consensus was to add vemurafenib (category 1) as a systemic therapy option for the treatment of patients with advanced or metastatic melanoma.</p>	<ol style="list-style-type: none"> Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Eng J Med 2011; 2507-2516. Prescribing Information: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/202429s000lbl.pdf 	15	0	0